NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LXRX shares have decreased by 16.7% and is now trading at $1.89. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Monday, April, 27th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.69) by $0.06. The biopharmaceutical company had revenue of $8 million for the quarter, compared to analysts' expectations of $7.18 million. Lexicon Pharmaceuticals had a net margin of 26.59% and a return on equity of 125.61%. View Lexicon Pharmaceuticals' earnings history.

6 Wall Street analysts have issued 1-year target prices for Lexicon Pharmaceuticals' stock. Their forecasts range from $2.10 to $9.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $4.53 in the next year. This suggests a possible upside of 139.4% from the stock's current price. View analysts' price targets for Lexicon Pharmaceuticals.

News coverage about LXRX stock has been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lexicon Pharmaceuticals earned a news impact score of -5.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutLexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 10,520,000 shares, a drop of 5.9% from the April 15th total of 11,180,000 shares. Based on an average daily trading volume, of 950,600 shares, the short-interest ratio is presently 11.1 days. Currently, 10.2% of the company's stock are sold short. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Geron (GERN), Orexigen Therapeutics (OREX), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Micron Technology (MU).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.76%), AQR Capital Management LLC (1.35%), Pictet Asset Management Ltd. (1.12%), Acadian Asset Management LLC (1.01%), State Street Corp (0.77%) and Bank of New York Mellon Corp (0.70%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Morgan Stanley, Spark Investment Management LLC, AXA, State Street Corp, Bank of New York Mellon Corp, Pinnacle Associates Ltd., and BlackRock Inc.. View insider buying and selling activity for Lexicon Pharmaceuticals.

LXRX stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, AQR Capital Management LLC, Federated Hermes Inc., Pictet Asset Management Ltd., Hancock Whitney Corp, WINTON GROUP Ltd, Squarepoint Ops LLC, and Two Sigma Advisers LP. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus, and Sam L Barker. View insider buying and selling activity for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $1.89.

Lexicon Pharmaceuticals has a market capitalization of $202.17 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.